ABSTRACT -Single-and 13-week repeated-dose toxicities of Geranti Bio-Ge Yeast ® , organic germanium fortified yeasts, were investigated in rats. Both sexes of Sprague-Dawley rats were orally administered once at a dose of 2,000 mg/kg in single-dose toxicity or daily for 13 weeks at doses of 500, 1,000 or 2,000 mg/kg in repeated-dose toxicity tests. In single-dose toxicity test to determine dose levels in repeated-dose toxicity study, the body weight gain was suppressed at 2,000 mg/kg, although no death, clinical signs and pathological findings related to the treatment were observed. In repeated-dose toxicity test, there were no clinical signs in animals administered up to 2,000 mg/kg, except one rat died due to a gavage error. In addition, no significant changes in feed consumption and body weight gain were obtained during the treatment period, in spite of week-to-week fluctuation of water consumption. There were no considerable changes in ophthalmoscopy, urinalysis, hematology and serum biochemistry, except a significant decrease in albumin/globulin ratio in males treated with 1,000 mg/kg. In contrast, a significant increase in relative heart weight was observed in both male and female rats treated with a high dose (2,000 mg/kg) of Geranti Bio-Ge Yeast ® . In microscopic examination, mild lesions were found sporadically in both control and treatment groups in a dose-independent manner. In spite of some alterations in water consumption, serum biochemistry and organ weights, such effects were not considered to include toxicopathological significance, based on the lack of dose-dependency, consistent time-course and gender relationship. Taken together, it is suggested that no observed adverse effect level (NOAEL) of Geranti Bio-Ge Yeast ® is considered to be over 2,000 mg/kg in rats, and that long-term oral intake in humans might not exert adverse effects.
INTRODUCTION
Germanium (Ge) is a grayish-white crystalline metal with atomic number of 32, atomic weight of 72.6 and specific gravity of 5.33 g/cm. Germanium is a naturally occurring trace element found in soil, water, plants and animal bodies, and daily intake in adults ranges from 0.367 to 1.5 mg (Tao and Bolger, 1997) . However, there is no evidence of any essential function in living organisms, and no germanium deficiency syndromes have been documented (Schauss, 1991) .
Despite no essential biological role, diverse germanium compounds have been reported to be biologically active in inducing erythropoietic (Hammett et al., 1992) , antimicrobial (Kaars Sijpesteijn et al., 1964) , antiviral (Aso et al., 1989) , antimutagenic (Kada et al., 1984; Han et al., 1992; Olsen et al., 1995; Gerber and Leonard, 1997; Lee et al., 1998) , antitumor Brutkiewicz and Suzuki, 1987; Jao et al., 1990; Gerber and Leonard, 1997; Kang et al., 2001) , analgesic (Suzuki and Taguchi, 1983) and immunomodulating (Aso et al., 1985; Nakada et al., 1993; Ikemoto et al., 1996) activities, in addition to diverse therapeutic effects (Goodman, 1988; Tao and Bolger, 1997) , along with antagonistic action on heavy metal poisoning (Han et al., 1992; Lee et al., 1998) . Thus, germanium-containing dietary supplements have become increasingly popular in recent years.
In spite of diverse effectiveness, the safety of germanium compounds is highly controversial. In fact, at least 31 human cases of germanium intoxication were reported of which 9 patients died (Tao and Bolger, 1997) . The most common clinical symptoms of germanium intoxication were renal failure, anemia and muscle weakness. In general, toxicity has been found to come from inorganic compounds such as germanium dioxide (GeO 2 ) and germanium tetrachloride. On the other hand, organic germaniums such as spirogermanium, germanium lactate citrate and carboxyethylgermanium sesquioxide (Ge-132) have been reported to exert negligible adverse effects, although the safety of organic germaniums is also in controversy (Tao and Bolger, 1997) . According to these findings, the possibility of the release of atomic germanium from an organic form is on the focus of argument, in addition to the toxicity of the organic compound itself.
Organic geranium can be extracted from medicinal plants containing high concentrations of germanium such as ginseng, aloes, garlic and Ganoderma lucidum Karst, or chemically synthesized from germanium dioxide and organic acids through catalysis (Asai, 1980; Tao and Bolger, 1997) . However, the extraction procedures cost too much, while purification procedures following chemical synthesis have not been proven to provide safe products, which limited its uses as a food or drug (Tao and Bolger, 1997) .
On the other hand, yeasts, used for thousands of years for brewing and baking, provide proteins, vitamins and minerals, and are known as the provider of the new age proteins (Nobohiro et al., 1980) . They also provide a high amount of vitamin B as a single food, contain enzymes that are crucial for the body's metabolic activation, and have been used widely as health foods. Also, organic germaniums have been successfully obtained from microorganisms, especially from yeasts (Klapcinska and Chmielowski, 1986; Vandyke et al., 1989; Slawson et al., 1992; Wei, 1992; Young and Tyk, 1997; Kushinirov, 2000) . Geranti Bio-Ge Yeast ® , a product of GerantiPharm Co., Ltd. (Seoul, Korea), is powdered yeasts containing biosynthetic organic germanium themselves. In the present study, we investigated overall toxic effects following longterm oral administration to rats with Geranti Bio-Ge Yeast ® up to a high dose (2,000 mg/kg) for 13 weeks.
MATERIALS AND METHODS

Test compound
Geranti Bio-Ge Yeast ® , dried yellowish powder of an edible yeast strain containing biosynthetic organic germanium, was stored at 4°C, dissolved in water, and administered in a volume of 10 ml/kg.
Test Animals
Specific pathogen-free male and female SpragueDawley rats (5 weeks old), purchased from Samtako Co., Ltd. (Osan, Korea), were housed in an environmentally-controlled room with temperature of 23 ± 2°C, relative humidity of 55 ± 10%, air ventilation of 10 − 15 times/hr, a 12-hr light/dark cycle of 150 − 300 lux, and feed and water available ad libitum.
Single-dose toxicity study
The test was performed according to the "Guidelines for Toxicity Tests of Drugs and Related Materia l s" p r ov i d e d b y t h e Ko r e a Fo o d a n d D r u g Administration (KFDA) (Korea Food and Drug Administration, 1999) . In brief, 5 rats of both sexes in each group were weighed, and administered with 2,000 mg/kg of freshly-prepared Geranti Bio-Ge Yeast ® or its vehicle (water) in a volume of 10 ml/kg. Clinical signs and mortality were examined every day for 14 days, and body weights were recorded on Days 0, 1, 3, 7 and 14 after administration. On Day 14, all rats were sacrificed, and the tissues showing lesions were examined under a microscope after formalin fixation, paraffin embedding and hematoxylin and eosin staining.
Repeated-dose toxicity study
The test was also performed according to the "Guidelines for Toxicity Tests of Drugs and Related Materials" provided by KFDA (Korea Food and Drug Administration, 1999) . Ten animals of both sexes in each group were weighed, and administered with freshly-prepared Geranti Bio-Ge Yeast ® at doses of 500, 1,000 or 2,000 mg/kg or its vehicle for 13 weeks. Vol. 29 No. 5 Clinical signs and mortality were examined every day throughout the experimental period, and body weights and feed and water consumptions were recorded every week. The animals were fasted after final administration for 24 hr and subjected to ophthalmologic examination. Urine was sampled for urinalysis from a part of the animals (6 rats/sex/group) during the fasting period. After blood collection for hematology and biochemistry, all rats were sacrificed under deep anesthesia with ether. Internal organs were removed, weighed, and gross findings were recorded. Also, the organs were examined under a microscope after formalin fixation, paraffin embedding, and hematoxylin-eosin staining.
Urine samples were analyzed by Combur 10 Test ® M paper (Roche, Germany) for color, turbidity, volume, specific gravity, pH, leukocytes, nitrite, protein, glucose, ketone, urobilinogen, bilirubin, occult blood and hemoglobin (Hb). For hematology, 1 ml of whole blood was collected into the CBC bottle (MEDI-LAND Co., Ltd., Korea) containing EDTA, and examined by a hematology autoanalyzer (CELL-DYN 3700, Abbott, USA) for total red blood cell (RBC) counts, Hb concentration, hematocrit (Hct), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), platelets, total white blood cell (WBC) counts and WBC differential counting (neutrophils, eosinophils, basophils, lymphocytes and monocytes). Reticulocytes were counted under a microscope after staining with methylene blue. Separately, prothrombin time (PT) and activated partial thromboplastin time (APTT) were measured in plasma obtained from sodium citrate-treated blood using an automatic coagulation time meter (ACL 7000, Instrumentation Lab., USA). Serum biochemical analysis was performed using an automatic analyzer (INTEGRA 400, Roche, Germany) and an electrolyte analyzer (AVL9181, Roche, Germany) for alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), γ-glutamyltranspeptidase (γ-GTP), lactate dehydrogenase (LDH), blood urea nitrogen (BUN), creatinine, total bilirubin, creatine kinase (CK), total protein, albumin, albumin/globulin (A/G) ratio, total cholesterol, triglycerides (TG), glucose, phosphorus (P), calcium (Ca), potassium (K), sodium (Na) and chloride (Cl) .
The experiments performed here were conducted according to Standard Operation Procedures (SOP) of Biotoxtech Co., Ltd. (Cheongwon, Korea) and the "Guide Principles in the Use of Animals in Toxicology" which had been adopted by the Society of Toxicology in 1989.
Statistical analysis
The data were expressed as the mean ± S.D., and analyzed for homogeneity of variance using Levene's test (Montgomery, 1984) . Tests of significance were performed using Dunnett's t-test (Montgomery, 1984) after ANOVA analysis for homogeneous data or an appropriate t-test following rank or logarithmic transformation, with p < 0.05 as a criterion of difference. Separately, the categorical values in urinalysis were compared using X 2 test.
RESULTS
Single-dose toxicity
During the experimental period, there were no animals dead, moribund or showing clinical signs in both control and treatment groups. However, the gain of body weights of male rats decreased a week after administration with Geranti Bio-Ge Yeast ® (2,000 mg/ kg), leading to significant lower weights (210.8 ± 8.6 g) than that (227.4 ± 7.1 g) of the control group on the final day (p<0.05) (Fig. 1) . In contrast, such a decrease in body weight gain was not found in female rats.
As necropsy findings, only one female rat in the control group showed slightly yellow liver as well as ( and ) and female ( and ) rats following single administration on Day 0 with 2,000 mg/kg of Geranti Bio-Ge Yeast ® ( and ) or its vehicle ( and ). * Significantly different from gender-matched control (p < 0.05).
pale kidneys. Inflammatory cell foci were observed at the lesions of pale kidneys in microscopic findings. Based on the results, the highest dose of Geranti BioGe Yeast ® in repeated-dose toxicity study was set at 2,000 mg/kg.
Repeated-dose toxicity
Geranti Bio-Ge Yeast ® , orally administered for 13 weeks to rats up to 2,000 mg/kg, did not induce any remarkable clinical signs or affect the body weight gain (Fig. 2) , although one female rat administered with a low dose (500 mg/kg) died on day 42, which was confirmed to be due to gavage error. No significant changes in feed consumption were obtained during the treatment period, in spite of week-to-week fluctuation of water consumption, leading to significant decreases at weeks 12 and 13 in females and males, respectively, treated with a high dose (2,000 mg/kg) of Geranti BioGe Yeast ® (Figs. 3 and 4 ). In addition, there were no considerable changes in ophthalmoscopy and urinalysis (Table 1) . While no alterations were detected in hematology (Table 2) , a significant decrease in albumin/globulin ratio was observed in serum biochemistry in only male rats treated with a medium dose (1,000 mg/kg) of Geranti Bio-Ge Yeast ® (p<0.05) ( Table 3 ). On the other hand, significant increases in the relative weight, but not absolute weight, of the heart were Vol. 29 No. 5 observed in both male and female rats treated with a high dose (2,000 mg/kg) of Geranti Bio-Ge Yeast ® (p<0.05) (Tables 4 and 5 ). In gross findings, however, no lesions were observed in organs including the heart, except unilateral brown discoloration of lungs in only two female rats treated with a medium dose (1,000 mg/ kg).
In microscopic examination, mild lesions, such as hypoplastic seminiferous tubules, renal pelvic inflammation and medullar mineralization, myocardial inflammatory cell foci, hepatic inflammatory cell foci and respiratory granulomatous inflammation, were found sporadically in both control and treatment groups in a dose-independent manner (Table 6 ). In particular, the female rat died on Day 42, during treatment with a low dose (500 mg/kg), displaying severe lung hemorrhage and congestion in gross examination and showing suppurative hemorrhagic alveolitis with foreign materials in alveolar space in microscopic findings, supportive of the inhalation of the test compound due to a gavage error.
DISCUSSION
It is well known that main pharmacological activities of germanium compounds include antimicrobial, antitumor and immunomodulating effects (Kaars Sijpesteijn et al., 1964; Aso et al., 1985 Aso et al., , 1989 Suzuki et al., 1985; Brutkiewicz and Suzuki, 1987; Goodman, 1988; Jao et al., 1990; Nakada et al., 1993; Ikemoto et al., 1996; Gerber and Leonard, 1997; Kang et al., 2001) . However, it has been reported that germanium compounds exhibit diverse toxicities. The most common signs and symptoms seen in patients were weight loss, fatigue, gastrointestinal disturbances including nausea, emesis and anorexia, anemia, muscle weakness and renal failure (Tao and Bolger, 1997) . The target organs of germaniums are kidneys (Sanai et al., 1991a (Sanai et al., , 1991b Schauss, 1991; Raisin et al., 1992; Hess et al., 1993) , muscles (Yim et al., 1999) , nerves (Matsumuro et al., 1993) and liver (Raisin et al., 1992) . It is believed that functional disorder of mitochondria is one of the toxic mechanisms, inferred from the characteristic features of swollen mitochondria in renal tubules and muscles (Matsumuro et al., 1993; Yim et al., 1999) .
Although the most common adverse effects of germanium have been reported to come from inorganic compounds, at least 4 reported cases in European countries were associated with the ingestion of organic germanium-lactate-citrate ( Van der Spoel et al., 1990; Krapf et al., 1992; Hess et al., 1993) . Accordingly, the safety of organic germaniums is in controversy. Interestingly, some preparations of organic germanium were confirmed to include high concentrations of inorganic germanium dioxide, which was claimed to be the organic Ge-132 or germanium-lactate-citrate of unknown purity (Tao and Bolger, 1997) . Since germanium dioxide is a starting material for these organic forms, it is not excluded that residual germanium dioxide could be found in the final products, depending on the thoroughness of good manufacturing practice. Otherwise, the possibility of the release of atomic germa- nium from the organic forms in the body, such as gastrointestinal tracts, liver, kidneys or muscles, is on the focus of argument.
Researches for the mass production of organic germaniums from microbes, rather than from plants or chemical synthesis, have been in progress. As a result, it was found that germanium can be stored through energy-independent passive binding to proteins within t h e b o d y o f t h e m i c r o b e s ( K l a p c i n s k a a n d Chmielowski, 1986; Wei, 1992; Young and Tyk, 1997;  
6.2 ± 0. Table 4 . Absolute organ weights of rats (n = 10) administered with Geranti Bio-Ge Yeast ® or its vehicle for 13 weeks. Boder and Wittrup, 2000) , and that the germaniumcontaining proteins could be successfully obtained from the microorganisms (Kushinirov, 2000) . Geranti Bio-Ge Yeast ® , the test material of the present study, is a crushed and dried powder of an edible yeast strain that can biosynthesize and concentrate protein-bound germaniums in it during culture. Noteworthily, both the dried and powdered yeasts exerted remarkable immunostimulating and anti-arthritis effects (unpublished data).
In previous genotoxicity tests, it was not found that Geranti Bio-Ge Yeast ® induced not only bacterial mutagenesis in Salmonella typhimurium and Escherichia coli strains, but also chromosomal aberration in Chinese hamster lung fibroblasts (Min et al., 2004) . Also, Geranti Bio-Ge Yeast ® was not found to have a potential for micronuclei formation in ICR mice up to 2,000 mg/kg. Furthermore, dried yeasts, before powdering, also did not exhibit any adverse effects following long-term oral treatment for 10 months in rats and dogs (Ahn et al., 2001a (Ahn et al., , 2001b .
Actually, acute oral toxicity of germanium compounds is low. It was reported that the LD 50 values in rats were 3,700 mg/kg and 11,000 -11,700 mg/kg for germanium dioxide and Ge-132, respectively (Asai, 1984; Vouk, 1986) . In the present single-dose toxicity study, no death, clinical signs and pathological findings related to the treatment were observed, although a high dose (2,000 mg/kg) of Geranti Bio-Ge Yeast ® suppressed the body weight gain in male rats, but not in females. It was known that germanium dioxide is highly toxic, resulting in 50% mortality following 4-week treatment at 100 -1,000 ppm in drinking water or diet (Rosenfeld and Wallace, 1953) . In contrast, Geranti Bio-Ge Yeast ® did not induce mortality, except minimal physiological changes. There were decreases in water consumption at weeks 12 and 13 in females and males, respectively, treated with 2,000 mg/kg, decrease in albumin/globulin ratio in males treated with 1,000 mg/kg, increase in the relative weight of heart in both males and females treated with 2,000 mg/ kg of Geranti Bio-Ge Yeast ® , and sporadic mild lesions in both control and treatment groups. In spite of some alterations in the water consumption, serum biochemistry and organ weights, however, such effects observed at extremely high doses were not considered to include toxicopathological significance, based on the lack of dose-dependency, consistent time-course and gender relationship.
As mentioned above, long-term exposure to inorganic germanium compounds is harmful even to death. In this context, the impurity of chemically-synthesized organic germanium compounds or release of inorganic germanium from biosynthetic organic preparations are on the focus in terms of their safety. As inferred from the results of this study, the release of inorganic germanium from Geranti Bio-Ge Yeast ® during the long-term (13 weeks) treatment with high doses (up to 2,000 mg/ kg) might be negligible. Thus, the organic features of germanium atom in Geranti Bio-Ge Yeast ® are believed to be devoid of acidic or enzymatic degradation in gastrointestinal tracts, liver, kidneys or muscles.
Taken together, in comparison with a lowest observed effect dose of 37.5 mg/kg of germanium dioxide or 26 mg/kg of germanium (Sanai et al., 1991a) , it is suggested that no observed adverse effect level (NOAEL) of Geranti Bio-Ge Yeast ® is considered to be 2,000 mg/kg in rats, and that long-term oral treat- 
